SOLICITATION NOTICE
B -- Tandem Repeat Gene Analysis
- Notice Date
- 9/7/2004
- Notice Type
- Solicitation Notice
- NAICS
- 541990
— All Other Professional, Scientific, and Technical Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-40177-NG
- Response Due
- 9/21/2004
- Archive Date
- 10/6/2004
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Renita Smith, Contract Specialist, Phone 301-496-8612, Fax 301-480-0241,
- E-Mail Address
-
holdcram@exchange.nih.gov, rs442i@nih.gov
- Description
- The National Cancer Institute (NCI), Tobacco Control Research Branch (TCRB), plans to procure on a sole source basis services for Tandem Repeat Gene Analysis: Association with Smoking Cessation Success in the ATBC Trial with BioServe Biotechnologies, Ltd., 1050 West Street, Laurel, MD 20707. This requirement will be procured in accordance with simplified acquisition procedures authorized in FAR Part 13. The North American Industry Classification System Code (NAICS) is 541990 and the Business Size Standard is $6M. This study will examine the relationship of genes to smoking behavior. In particular, NCI proposes to determine the association of variations in genes in brain reward pathways with smoking cessation success. This project also represents a collaborative effort among NCI divisions and staff, including scientists from the Division of Cancer Control and Population Sciences (DCCPS), the Division of Cancer Epidemiology and Genetics (DCEG), the Center for Cancer Research (CCR), and the Core Genotyping Facility (CGF). Samples for these analyses will be drawn from the Alpha-Tocopherol Beta Carotene Cancer Prevention (ATBC) Study, originally a longitudinal, cohort study of heavy smoking Finnish males exploring the effectiveness of a nutritional intervention in preventing cancer. The Cancer Prevention Studies Branch (CPSB) has been overseeing a number of follow-up analyses based on the ATBC trial and they have provided the samples that will be used for this project. Given their expertise with this dataset, CPSB/CCR will also offer general oversight of the project and, when necessary, provide clarification on features of the original ATBC database. The current project will utilize a nested case-control design and will investigate the potential role of a number of important genes associated with smoking cessation. The objectives of this study are to (1) identify the prevalence among the ATBC participants of variations in key genes associated with nicotine metabolism and brain reward pathways believed to be linked with smoking behavior, (2) assess the association of each of these variations with success or failure of smoking cessation defined as a qualitative or dichotomous variable, and (3) investigate whether any of those variants are predictive of cessation success as a quantitative or continuous variable (e.g., regression, survival analysis). BioServe Biotechnologies, Ltd. (BioServe) has completed the DNA extraction for 840 ATBC participant samples from whole blood, and conducted extensive normalization, re-quantitation, and aliquotting of the remaining samples of previously extracted DNA, which arrived in less-than-optimal condition from the NCI repository. They currently have in their possession all of the samples needed to complete this project, aliquoted and/or plated in the format necessary for these analyses. As part of that effort, the current project will be performed in parallel with an ongoing project being conducted by DCEG/NCI that is analyzing samples drawn from the Prostate Lung Colorectal Ovarian Cancer Prevention (PLCO) Trial to explore the possible genetic determinants of smoking. Performing these two projects in parallel presents a unique opportunity to carry out synchronized analyses among smokers drawn from different samples with varying baseline smoking topographies. In addition, this will allow for further collaboration between DCCPS and DCEG, the sharing of resources, and opportunities to present the findings to the scientific community simultaneously. BioServe Biotechnologies is the only source known to the NCI that can provide the services required to fulfill this requirement. They have extensive experience working with this sample set and currently have possession of all the samples needed to complete this analysis. BioServe has extensive success in completing projects for NCI's Cancer Prevention Studies Branch and DCEG. Projects include similar genotyping work using samples from the ATBC study, including multiple SNPs in both tobacco-related and non-tobacco-related genes. BioServe provided extremely accurate and reproducible results on the SNP analysis and prevalence studies with the ATBC dataset. This is not a request for competitive quotation. However, if any interested party believes it can perform the above requirement, it may submit a statement of capabilities. The statement of capabilities and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 1:00 PM EST, September 21 , 2004. If you have any questions they must be submitted in writing to Malinda Holdcraft, Purchasing Agent, at holdcram@exchange.nih.gov or by fax 301-402-4513. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Solicitation number NCI- 40177-NG must be stated on all correspondence.
- Place of Performance
- Address: Maryland
- Zip Code: 20852
- Country: USA
- Zip Code: 20852
- Record
- SN00666754-W 20040909/040907212741 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |